CCO Oncology Podcast
Podcast autorstwa Clinical Care Options
189 Odcinki
-
Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC
Opublikowany: 25.03.2025 -
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer
Opublikowany: 20.02.2025 -
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
Opublikowany: 10.02.2025 -
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer
Opublikowany: 9.01.2025 -
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies
Opublikowany: 22.10.2024 -
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations
Opublikowany: 16.10.2024 -
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Opublikowany: 1.10.2024 -
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance
Opublikowany: 30.09.2024 -
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC
Opublikowany: 6.09.2024 -
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC
Opublikowany: 5.09.2024 -
ROS1-Alterations and Molecular Testing in Advanced NSCLC
Opublikowany: 28.08.2024 -
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
Opublikowany: 5.08.2024 -
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Opublikowany: 22.07.2024 -
Current Clinical Practice and NCCN Guidelines for CLL/SLL
Opublikowany: 18.07.2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
Opublikowany: 12.07.2024 -
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
Opublikowany: 11.07.2024 -
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Opublikowany: 9.07.2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for AML
Opublikowany: 8.07.2024 -
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
Opublikowany: 5.07.2024 -
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
Opublikowany: 14.05.2024
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
